Yang M.-C.JYH-HONG LEEYAO-HSU YANGBOR-LUEN CHIANG2020-12-082020-12-0820081756-1841https://www.scopus.com/inward/record.uri?eid=2-s2.0-54949156508&doi=10.1111%2fj.1756-185X.2008.00336.x&partnerID=40&md5=05d146527ce865deaafeac3b7501e0d8https://scholars.lib.ntu.edu.tw/handle/123456789/525028Juvenile dermatomyositis is a chronic multisystemic disease. It is believed to be of autoimmune aetiology and is characterized by the presence of vasculitis affecting striated muscle and skin. Calcinosis occurs in about 40% of cases. We report a case of a 10-year-old girl diagnosed with juvenile dermatomyositis who presented with difficulty in walking and inability to completely extend the four extremities due to calcinosis universalis. Calcinosis had progressed despite a 3-year administration of diltiazem, hydroxychloroquine, aluminium hydroxide, cyclosporin, and probenecid. The introduction of monthly intravenous immunoglobulin therapy for 15 months lessened disease activity, and markedly regressed calcinosis, and improved functional outcome. ? 2008 Asia Pacific League of Associations for Rheumatology.[SDGs]SDG3aluminum hydroxide; cyclosporin; diltiazem; hydroxychloroquine; immunoglobulin; methotrexate; methylprednisolone; prednisolone; probenecid; anamnesis; article; calcinosis; calcinosis universalis; case report; clinical protocol; dermatomyositis; disease activity; disease course; drug pulse therapy; female; follow up; human; human tissue; juvenile dermatomyositis; low drug dose; muscle biopsy; myopathy; priority journal; school child; scoring system; soft tissue calcification; walking difficultyjournal article10.1111/j.1756-185X.2008.00336.x2-s2.0-54949156508